MAIDENHEAD, England,
April 22, 2013 /PRNewswire/ --
Who: ViroPharma, an international
biopharmaceutical company committed to developing and
commercialising innovative solutions for physicians to address the
unmet medical needs of patients living with diseases that have few,
if any, clinical therapeutic options.
What: European Congress of Endocrinology,
Bella Center, Copenhagen, Denmark,
27 April - 1 May
- The ViroPharma symposium, 'A new paradigm in the
treatment of patients with adrenal
insufficiency', 28 April
2013, 18.30-20.00, Auditorium 15, will bring together an
internationally renowned faculty to discuss:
- Challenges of meeting needs of adrenal insufficiency (AI)
patients with immediate release hydrocortisone
- The impact of current therapies on well-being and quality of
life
- Latest research on the circadian rhythm of cortisol, including
its importance in metabolism and cardiovascular health
- Innovative new approaches for optimising the management of
AI
- Two posters will be presented at the ECE scientific
sessions:
- Poster 1: European Adrenal Insufficiency Registry (EU-AIR): a
comparative observational study of glucocorticoid replacement
therapy. Poster P49. Ekman et al.: Tuesday 30 April, 13:00-14:00 PDT, Poster hall.
- Poster 2: Management of Addison's disease patients using dual
release hydrocortisone during periods of intercurrent illness
(ICI). Poster P24. Johannsson et al.: Monday 29 April, 13:00:14:00
PDT, Poster hall.
Symposium faculty:
Co-Chairs:
Eystein Husebye, Bergen, Norway; Ulla
Feldt-Rasmussen, Copenhagen,
Denmark
Panel: Eve Van
Cauter, Chicago, USA; Ashley
Grossman, Oxford, UK;
Anna Nilsson, Gothenburg, Sweden; Marcus Quinkler,
Berlin, Germany
For further information about ViroPharma, visit
http://www.viropharma.com/
For further information about ECE, visit
http://www.ece2013.org/
About ViroPharma
Incorporated
ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercializing novel solutions
for physician specialists to address unmet medical needs of
patients living with diseases that have few if any clinical
therapeutic options, including C1 esterase inhibitor deficiency,
treatment of prolonged, acute, convulsive seizures in children and
adolescents, adrenal insufficiency, and C. difficile
infection (CDI). Our goal is to provide rewarding careers to
employees, to create new standards of care in the way serious
diseases are treated, and to build international partnerships with
the patients, advocates, and health care professionals we
serve.